Encoberminogene rezmadenovec

瑞艾恩可基

Report date: 2025/07/16 17:21:30

Base Information

Drug NameEncoberminogene rezmadenovec
Drug Alias NameAdVEGF-All6A+AdVEGF-A116A+ gene therapy (XyloCor Therapeutics)AdVEGFXC1XC-001
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vector
Mechanisms of ActionVascular endothelial growth factor gene transference
TargetsVascular endothelial growth factor
Therapy Area/IndicationsIschemiaCoronary Artery DiseaseAngina Pectoris +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCornell University
China Registration ClassN/A

Develop Information

Active CompaniesXylocor Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsIschemiaCoronary Artery DiseaseAngina Pectoris +[5] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A